Skip to main content
. 2020 Mar 13;11(12):3446–3453. doi: 10.7150/jca.41135

Figure 1.

Figure 1

The expression levels of miR-186 in cisplatin-resistant and the parental ovarian cancer cells. (A) (B) Cells were treated with cisplatin for 48 hours, and then the IC50 of cisplatin was evaluated by cell viability assay. (C) (D) The expression levels of miR-186 was analyzed by quantitative real-time PCR in cisplatin-resistant and the parental ovarian cancer cells. *P<0.05, **P<0.01, ***P<0.001.